Nrx Pharmaceuticals Inc (NRXP)
$1.25
Live
Performance
- $1.24$1.32$1.25
0.8%
Downside
Day's Volatility :6.06%
Upside
5.3%
- $1.10$7.33$1.25
12.0%
Downside
52 Weeks Volatility :85.0%
Upside
82.95%
Returns
| Period | Nrx Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -46.58% | 3.6% | 0.0% |
6 Months | -58.33% | 10.2% | 0.0% |
1 Year | -55.8% | 19.6% | 0.0% |
3 Years | -98.83% | 16.8% | -23.0% |
Highlights
Market Capitalization | 14.0M |
Book Value | -$1.71 |
Earnings Per Share (EPS) | -2.68 |
Wall Street Target Price | 31.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -115.97% |
Return On Equity TTM | -682.61% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -23.3M |
Diluted Eps TTM | -2.68 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.04 |
EPS Estimate Next Year | -1.67 |
EPS Estimate Current Quarter | -0.69 |
EPS Estimate Next Quarter | -0.69 |
Analyst Recommendation
Buy
88%Buy
11%Hold
0
0%Sell
Based on 9 Wall street analysts offering stock ratings for Nrx Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
- Current
- 1M Ago
- 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 2420.0%
Current $1.25
Target $31.50
Technicals Summary
Sell
Neutral
Buy
Nrx Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nrx Pharmaceuticals Inc | -24.24% | -58.33% | -55.8% | -98.83% | -94.85% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nrx Pharmaceuticals Inc | 0.36 | NA | NA | -3.04 | -6.83 | -1.16 | NA | -1.71 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nrx Pharmaceuticals Inc | Buy | $14.0M | -94.85% | 0.36 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Nrx Pharmaceuticals Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 141.2%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 143.6%
Institutional Holdings
Vanguard Group Inc
2.24%AdvisorShares Investments, LLC
1.01%Geode Capital Management, LLC
0.61%BlackRock Inc
0.27%Virtu Financial LLC
0.16%State Street Corp
0.16%
Company Information
Organization | Nrx Pharmaceuticals Inc |
Employees | 0 |
CEO | Mr. Richard Clavano Narido |
Industry | Services |
